The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain

BackgroundDSB, the 3-O-(3',3'dimethylsuccinyl) derivative of betulinic acid, blocks the last step of protease-mediated processing of HIV-1 Gag precursor (Pr55Gag), which leads to immature, noninfectious virions. When administered to Pr55Gag-expressing insect cells (Sf9), DSB inhibits the assembly and budding of membrane-enveloped virus-like particles (VLP). In order to explore the possibility that viral factors could modulate the susceptibility to DSB of the VLP assembly process, several viral proteins were coexpressed individually with Pr55Gag in DSB-treated cells, and VLP yields assayed in the extracellular medium.ResultsWild-type Vif (Vifwt) restored the VLP production in DSB-treated cells to levels observed in control, untreated cells. DSB-counteracting effect was also observed with Vif mutants defective in encapsidation into VLP, suggesting that packaging and anti-DSB effect were separate functions in Vif. The anti-DSB effect was abolished for VifC133S and VifS116V, two mutants which lacked the zinc binding domain (ZBD) formed by the four H108C114C133H139 coordinates with a Zn atom. Electron microscopic analysis of cells coexpressing Pr55Gag and Vifwt showed that a large proportion of VLP budded into cytoplasmic vesicles and were released from Sf9 cells by exocytosis. However, in the presence of mutant VifC133S or VifS116V, most of the VLP assembled and budded at the plasma membrane, as in control cells expressing Pr55Gag alone.ConclusionThe function of HIV-1 Vif protein which negated the DSB inhibition of VLP assembly was independent of its packaging capability, but depended on the integrity of ZBD. In the presence of Vifwt, but not with ZBD mutants VifC133S and VifS116V, VLP were redirected to a vesicular compartment and egressed via the exocytic pathway.

[1]  F. Boisvert,et al.  Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation , 1995, Journal of virology.

[2]  K. Lee,et al.  Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. , 1996, Journal of medicinal chemistry.

[3]  E. Freed,et al.  Human immunodeficiency virus type 1 assembly, release, and maturation. , 2007, Advances in pharmacology.

[4]  Erez Pery,et al.  Identification of an APOBEC3G Binding Site in Human Immunodeficiency Virus Type 1 Vif and Inhibitors of Vif-APOBEC3G Binding , 2007, Journal of Virology.

[5]  David E. Martin,et al.  Determinants of activity of the HIV-1 maturation inhibitor PA-457. , 2006, Virology.

[6]  D. Trono,et al.  Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis , 1995, Journal of virology.

[7]  Pierre Boulanger,et al.  The 3-O-(3’,3’-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells , 2007, Antiviral therapy.

[8]  M. Hammarskjöld,et al.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines , 1997, Journal of virology.

[9]  B. Carlson,et al.  Association of Human Immunodeficiency Virus Type 1 Vif with RNA and Its Role in Reverse Transcription , 2000, Journal of Virology.

[10]  S. S. Hong,et al.  Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells , 1992, Journal of virology.

[11]  B. Strack,et al.  Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway* , 2004, Journal of Biological Chemistry.

[12]  K. Ravichandran,et al.  Human Immunodeficiency Virus Type 1 Nef Associates with Lipid Rafts To Downmodulate Cell Surface CD4 and Class I Major Histocompatibility Complex Expression and To Increase Viral Infectivity , 2004, Journal of Virology.

[13]  E. Freed,et al.  The cell biology of HIV-1 and other retroviruses , 2006, Retrovirology.

[14]  K. Sano,et al.  Anti-Human Immunodeficiency Virus Activity of YK-FH312 (a Betulinic Acid Derivative), a Novel Compound Blocking Viral Maturation , 2001, Antimicrobial Agents and Chemotherapy.

[15]  J. Mouscadet,et al.  The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[16]  B. Gay,et al.  Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles , 1995, Journal of virology.

[17]  É. Cohen,et al.  Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae , 2004, Retrovirology.

[18]  C. Jones,et al.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41 , 1997, Journal of virology.

[19]  P. Sova,et al.  Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity , 1994, Journal of virology.

[20]  L. Selig,et al.  HEED, the Product of the Human Homolog of the Murineeed Gene, Binds to the Matrix Protein of HIV-1* , 1999, The Journal of Biological Chemistry.

[21]  R. Gorelick,et al.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles , 1995, Journal of virology.

[22]  C. Tian,et al.  Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. , 2006, Virology.

[23]  Morris S. Jones,et al.  A Conserved Dileucine-Containing Motif in p6gag Governs the Particle Association of Vpx and Vpr of Simian Immunodeficiency Viruses SIVmac and SIVagm , 1999, Journal of Virology.

[24]  E. Freed,et al.  HIV-1 gag proteins: diverse functions in the virus life cycle. , 1998, Virology.

[25]  U. Schubert,et al.  Human Immunodeficiency Virus Type 1 Vpr Protein Is Incorporated into the Virion in Significantly Smaller Amounts than Gag and Is Phosphorylated in Infected Cells , 2000, Journal of Virology.

[26]  C. Aiken,et al.  Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation , 2004, Journal of Virology.

[27]  A. Friedler,et al.  Human immunodeficiency virus type 1 Vif‐derived peptides inhibit the viral protease and arrest virus production , 1998, FEBS letters.

[28]  M. Resh,et al.  Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids , 1994, Journal of virology.

[29]  C. Aiken,et al.  The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid , 2004, Retrovirology.

[30]  P Boulanger,et al.  Morphopoietic determinants of HIV-1 Gag particles assembled in baculovirus-infected cells. , 1998, Virology.

[31]  E. Decroly,et al.  Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. , 2001, The Journal of general virology.

[32]  E. Freed,et al.  Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions , 1996, Journal of virology.

[33]  B. Spire,et al.  Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins. , 1998, The Journal of general virology.

[34]  H. Kalbitzer,et al.  Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. , 1996, Virology.

[35]  F. Kirchhoff,et al.  Proline 35 of Human Immunodeficiency Virus Type 1 (HIV-1) Vpr Regulates the Integrity of the N-Terminal Helix and the Incorporation of Vpr into Virus Particles and Supports the Replication of R5-Tropic HIV-1 in Human Lymphoid Tissue Ex Vivo , 2007, Journal of Virology.

[36]  E. Stephens,et al.  Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtype C isolates and extensive variation in a proposed nuclear transport inhibition signal. , 2001, AIDS research and human retroviruses.

[37]  E. Freed,et al.  Retrovirus budding. , 2004, Virus research.

[38]  E. Decroly,et al.  The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles. , 2005, Biochemical and biophysical research communications.

[39]  Curtis McMurtrey,et al.  3-O-(3′,3′-Dimethysuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency Virus Type 1 Gag Precursor Assembled In Vitro , 2006, Journal of Virology.

[40]  R. Murali,et al.  Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Freed,et al.  Genetic Evidence for an Interaction between Human Immunodeficiency Virus Type 1 Matrix and α-Helix 2 of the gp41 Cytoplasmic Tail , 2000, Journal of Virology.

[42]  Xianghui Yu,et al.  Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. , 2007, Organic & biomolecular chemistry.

[43]  J. Kappes,et al.  The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures , 1995, Journal of virology.

[44]  S. Höglund,et al.  A Putative α-Helical Structure Which Overlaps the Capsid-p2 Boundary in the Human Immunodeficiency Virus Type 1 Gag Precursor Is Crucial for Viral Particle Assembly , 1998, Journal of Virology.

[45]  M. Malim,et al.  Mutational Analysis of the Human Immunodeficiency Virus Type 1 Vif Protein , 1999, Journal of Virology.

[46]  A. Rein,et al.  RNA is a structural element in retrovirus particles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Resh Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell membranes and makes viral particles. , 2005, AIDS reviews.

[48]  M. Khan,et al.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. , 2003 .

[49]  A. Kaplan,et al.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions , 1994, Journal of virology.

[50]  L. Selig,et al.  Interaction with the p6 Domain of the Gag Precursor Mediates Incorporation into Virions of Vpr and Vpx Proteins from Primate Lentiviruses , 1999, Journal of Virology.

[51]  D. Gabuzda,et al.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains , 1995, Journal of virology.

[52]  C. Labranche,et al.  Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. , 2004, Virology.

[53]  C. Dauguet,et al.  Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity , 1995, Journal of virology.

[54]  Wesley I. Sundquist,et al.  Biochemical Analyses of the Interactions between Human Immunodeficiency Virus Type 1 Vpr and p6Gag , 2001, Journal of Virology.

[55]  J. Cunningham,et al.  Visualization of Retroviral Replication in Living Cells Reveals Budding into Multivesicular Bodies , 2003, Traffic.

[56]  C. Aiken,et al.  Inhibition of HIV-1 Maturation via Drug Association with the Viral Gag Protein in Immature HIV-1 Particles* , 2005, Journal of Biological Chemistry.

[57]  B. Gay,et al.  Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells , 1994, Journal of virology.

[58]  David E. Martin,et al.  PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Murali,et al.  Functional Role of Residues Corresponding to Helical Domain II (Amino Acids 35 to 46) of Human Immunodeficiency Virus Type 1 Vpr , 2000, Journal of Virology.

[60]  C. Aiken,et al.  Betulinic acid derivatives as HIV-1 antivirals. , 2005, Trends in molecular medicine.

[61]  H. Kräusslich,et al.  Virion Incorporation of Human Immunodeficiency Virus Type 1 Nef Is Mediated by a Bipartite Membrane-Targeting Signal: Analysis of Its Role in Enhancement of Viral Infectivity , 1998, Journal of Virology.

[62]  M. Foti,et al.  HIV‐1 Egress is Gated Through Late Endosomal Membranes , 2003, Traffic.

[63]  C. Aiken,et al.  Disassembly of Human Immunodeficiency Virus Type 1 Cores In Vitro Reveals Association of Nef with the Subviral Ribonucleoprotein Complex , 2003, Journal of Virology.

[64]  Kunio Nagashima,et al.  In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat) , 2006, Journal of Virology.

[65]  K. Strebel,et al.  Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein , 1996, Journal of virology.

[66]  B. Roques,et al.  NMR structure of the HIV-1 regulatory protein VPR. , 2003, Journal of molecular biology.

[67]  E. Freed,et al.  Cell-Type-Dependent Targeting of Human Immunodeficiency Virus Type 1 Assembly to the Plasma Membrane and the Multivesicular Body , 2004, Journal of Virology.

[68]  S. Pettit,et al.  Proteolytic Processing of the P2/Nucleocapsid Cleavage Site Is Critical for Human Immunodeficiency Virus Type 1 RNA Dimer Maturation , 2001, Journal of Virology.

[69]  B. Spire,et al.  Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor , 1997, Journal of virology.

[70]  É. Cohen,et al.  Incorporation of Vpr into Human Immunodeficiency Virus Type 1 Requires a Direct Interaction with the p6 Domain of the p55 Gag Precursor* , 1999, The Journal of Biological Chemistry.

[71]  J. Goncalves,et al.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. , 2004, Genes & development.

[72]  M. Khan,et al.  High Level Expression of Human Immunodeficiency Virus Type-1 Vif Inhibits Viral Infectivity by Modulating Proteolytic Processing of the Gag Precursor at the p2/Nucleocapsid Processing Site* , 2004, Journal of Biological Chemistry.

[73]  Y. Xiong,et al.  Characterization of a novel Cullin5 binding domain in HIV-1 Vif. , 2007, Journal of molecular biology.

[74]  S. S. Hong,et al.  Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. , 1991, Virology.